Results 71 to 80 of about 21,722 (233)

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

Impact of glucuronide interferences on therapeutic drug monitoring of posaconazole by tandem mass spectrometry [PDF]

, 2010
Background: Posaconazole is a novel antifungal drug for oral application intended especially for therapy of invasive mycoses. Due to variable gastrointestinal absorption, adverse side effects, and suspected drug-drug interactions, therapeutic drug ...
Burghardt, Stephan, Krueger, Ralf, Lackner, Karl J., Vogelsberger, Rita, Vogeser, Michael   +4 more
core   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review assessed 52 biomarkers predicting systemic therapy response and adverse events in atopic dermatitis. Most studies focused on dupilumab, and findings were inconsistent. IgE and eosinophils were largely non‐predictive, though elevated eosinophils and LDH sometimes indicated poorer outcomes.
Eva Hilger, Kaitlyn Chan, Alphonsus Yip, Xingyue Maria Wang, Conor Broderick, Bernd Arents, Karin van Bart, Kilian Eyerich, Joseph Rastrick, Stephan Weidinger, Carsten Flohr, on behalf of the BIOMAP Consortium   +11 more
wiley   +1 more source

Technologies for restricting mould growth on baled silage [PDF]

, 2007
End of project reportSilage is made on approximately 86% of Irish farms, and 85% of these make some baled silage. Baled silage is particularly important as the primary silage making, storage and feeding system on many beef and smaller sized farms, but is
Clipson, Nicholas J.W., Doohan, Fiona, Doyle, Evelyn M., Egan, Damian, Forristal, Dermot, Frisvad, Jens C., Fuller, Hubert T., Laffin, Christopher, McEniry, Joseph, McNally, Gerard M., Nielsen, Kristian F., O'Brien, Martin, O'Kiely, Padraig, Small, Christopher M.   +13 more
core  

Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation. [PDF]

, 2009
International audienceBACKGROUND: Mycophenolate mofetil, a prodrug of mycophenolic acid (MPA), is used during non-myeloablative and reduced-intensity conditioning haematopoetic stem cell transplantation (HCT) to improve engraftment and reduce graft ...
Debord, Jean, Deconinck, Eric, Kantelip, Jean-Pierre, Larosa, Fabrice, Legrand, Faezeh, Marquet, Pierre, Royer, Bernard, Saint-Marcoux, Franck   +7 more
core   +3 more sources

The Role of Belatacept‐Use and Senescence on Infectious and Mortality Complications After Kidney Transplantation

Transplant Infectious Disease, EarlyView.
ABSTRACT Introduction Studies evaluating the incidence of infections after belatacept as a substitute for calcineurin inhibitors (CNI) or antimetabolite in kidney transplant (KT) yielded conflicting results. We compared infectious outcomes after belatacept‐use to no belatacept‐use in KT recipients.
Hareesh Singam, Abdinoor Abdi, Wyatt Tarter, Ben Langworthy, Adam Bregman, Karam M. Obeid   +5 more
wiley   +1 more source

Adaptive evolution of drug targets in producer and non-producer organisms [PDF]

, 2012
Mycophenolic acid (MPA) is an immunosuppressive drug produced by several fungi in Penicillium subgenus Penicillium. This toxic metabolite is an inhibitor of IMP dehydrogenase (IMPDH). The MPA biosynthetic cluster of P.
Balzarini, Bentley, Bjarne G. Hansen, Chooi, Christian S. Kaas, Collart, Farazi, Frisvad, Frisvad, Gao, Geu-Flores, Hansen, Hansen, Hans J. Genee, Hartman, Hedstrom, Hoff, Jakob B. Nielsen, Jenks, Jens C. Frisvad, Khersonsky, Kohler, Kohler, Lightfoot, Link, Lizbeth Hedstrom, MacPherson, Nimmesgern, Norholm, O'Brien, Regueira, Saitou, Sintchak, Tracewell, Uffe H. Mortensen, van den Berg, Wang, Wilson, Wilson, Wu, Xin E. Sun   +40 more
core   +1 more source

Role of BK Virus CTLs in the Treatment of BK Virus–Associated Nephropathy in Kidney‐Transplant and Hematopoietic Cell Transplant Recipients

Transplant Infectious Disease, EarlyView.
Third‐party, BK virus‐specific cytotoxic T lymphocytes (CTLs) were safe and effective in reducing viremia in kidney and stem cell transplant recipients with BK virus nephropathy. However, they did not improve kidney function. Earlier administration may be more beneficial before nephropathy and irreversible damage occur.
Amanda Olson, Ye Ethan Li, Rafet Basar, Pinaki Banerjee, Indresh Kaur, Glorette Abueg, Melihate Sylejmani, Nadima Uprety, Rejeena Shrestha, Francia Reyes Silva, Valda Page, Richard E. Champlin, Dimitrios P. Kontoyiannis, Roy F. Chemaly, Elizabeth J. Shpall, Linda Moore, Osama A. Gaber, Katayoun Rezvani, Ala Abudayyeh   +18 more
wiley   +1 more source

No Increased Risk of Infection Following a Protocol Change to Decrease Duration of Perioperative Antibiotic Prophylaxis in Liver Transplantation

Transplant Infectious Disease, EarlyView.
There was no increased rate of surgical site infection or bacteremia in liver transplant recipients following a decrease in perioperative antibiotic prophylaxis duration, with a change from 2.4% to 2.8% in patients hospitalized prior to transplant and 7.5% to 2.9% in other patients.
Hutton Brandon, Crystal M. Truax, Eduardo Rodriguez Zarate, Brandon J. Tritle, Hannah Imlay   +4 more
wiley   +1 more source